With Second-Gen Test Menu in Place, Rosetta Genomics Sets Sights on Third-Gen Pipeline

Unlike the three tests that the company currently markets and the five "Gen 2" tests that it expects to launch by the end of 2011, the new "Gen 3" assays will not focus on oncology and will interrogate body fluids rather than tissue samples, a company official said.